Breaking Through 4 Critical Bottlenecks in CGT Manufacturing
Discover strategic ways to overcome cell & gene therapy's biggest manufacturing barriers
Cell and gene therapy (CGT) manufacturing faces a critical paradox: therapies that could save lives are stuck in bottlenecks while patients wait. From QA/QC delays that push infusion timelines to the breaking point, to equipment drift that threatens batch integrity, to the "silver tsunami" of workforce knowledge walking out the door—these aren't just operational challenges. They're clinical risks.
This insightful industry brief exposes four systemic bottlenecks that are holding back the CGT revolution and reveals how leading manufacturers are leveraging digital transformation to shatter them. You'll discover proven strategies to compress vein-to-vein timelines, ensure site-to-site consistency, capture tribal knowledge before it's lost, and prevent silent equipment failures before they compromise batches. The path to scalable, compliant CGT manufacturing isn't incremental improvement—it's a fundamental reimagining of how quality gets built into every step.
You'll Learn:
- How digital workflows eliminate days from QA/QC release cycles and reduce chain-of-identity failure points.
- Why site-to-site variability threatens regulatory approval and how standardized digital process control solves it.
- How to protect against equipment drift and workforce knowledge loss before they become compliance nightmares.
Trusted By
Why Digital Manufacturing Is Now Non-Negotiable
CGT manufacturing operates in a batch-of-one world where traditional approaches simply can't keep pace. Manual batch records, paper-based standard operating procedures (SOPs), and disconnected systems create delays manufacturers can't afford and variability regulators won't tolerate. Modern digital manufacturing applications transform how quality gets embedded into execution—moving from after-the-fact reviews to real-time verification and from tribal knowledge to intelligent workflows. This isn't about going paperless; it's about building quality at the source, preventing deviations before they occur, and creating the data integrity foundation that both regulators and patients demand.
See what MasterControl users are saying
Ready to Break Through in CGT Manufacturing?
Get the industry brief and discover proven strategies to transform your CGT operations.
Download the BriefQuestions About Our CGT Industry Brief Answered
What are the four critical bottlenecks impacting cell and gene therapy manufacturing?
QA/QC and logistics delays, comparability and tech transfer challenges, workforce variability issues, and equipment drift are four major bottlenecks. Download the brief to learn how to overcome each bottleneck strategically and improve patient treatment timelines.
What is the "silver tsunami" concept addressed in the brief, and why does it matter for CGT manufacturers?
The “silver tsunami” embodies how retirement of experienced workers combined with high turnover creates unique risks in operator-dependent CGT processes. Download the full brief to learn how to approach this concept to minimize negative impacts on critical manufacturing and decisions.
How does MasterControl's platform specifically address the unique challenges of CGT manufacturing?
MasterControl offers purpose-built solutions for the critical phase between basic digitization and full enterprise orchestration where most advanced therapy manufacturers operate today. Download the full brief to learn all the ways MasterControl’s platform and features are strategically designed to help eliminate these common CGT hurdles using a Quality-at-the-Source approach.
Why is equipment drift such a critical compliance risk?
Silent performance degradation compromises batches before detection. Discover how connected asset management monitors parameters continuously and prevents out-of-spec equipment use.
MasterControl Manufacturing Excellence for CGT
Purpose-built for the unique demands of cell and gene therapy manufacturing, MasterControl Manufacturing Excellence (Mx) embeds quality directly into execution. Intelligent workflows with built-in guardrails prevent deviations, enforce training, link equipment status to batch eligibility, and flag exceptions in real time.
-
Quality Execution
MasterControl prevents deviations before they occur through in-line verification steps that validate each action against approved process parameters, ensuring quality is built at the source rather than reviewed after the fact.
-
Training Enforcement
The platform automatically verifies operator qualifications at the moment of execution, ensuring only trained personnel perform critical steps and creating an audit trail that satisfies regulatory requirements without manual tracking.
-
Equipment Intelligence
Connected asset management continuously monitors equipment performance against validated parameters and automatically prevents out-of-spec equipment from being used, eliminating silent drift that threatens batch quality and compliance.
-
Real-Time Oversight
Intelligent dashboards flag process exceptions instantly for immediate QA intervention, reducing after-the-fact quality reviews and accelerating time-sensitive release decisions that compressed CGT timelines demand for successful patient outcomes.
